3006 - Stereotactic Body Radiotherapy for Renal Cancer in a Latin American Country: Feasibility, Outcomes and Experience from an Academic Center
Presenter(s)
G. Ulloa Sr1, C. Retamal2, C. Salazar2, T. Merino1, E. F. Vines1, P. Muñoz-Schuffenegger1, P. Reyes Sr1, G. Antunez1, and J. P. Canales1; 1Radiation Oncology Unit, Department of Hematology - Oncology, Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Pontificia Universidad Católica de Chile, Santiago, Chile
Purpose/Objective(s): The hypothesis is that stereotactic body radiotherapy (SBRT) for renal cancer is feasible in a Latin American setting and achieves high local tumor control rates and progression-free survival, supporting its role as an alternative to surgery in resource-limited environments. The primary objective is to assess local control (LC). Secondary objectives include progression-free survival (PFS), overall survival (OS), and treatment-related toxicity.
Materials/Methods: A retrospective analysis was conducted on patients with localized or oligoprogressive renal cancer treated with SBRT between July 2021 and January 2025 at one institution. Patients were ineligible for surgery or declined surgical management. SBRT was delivered using image-guided radiotherapy techniques. LC, PFS, and OS were estimated at 6, 12, 18, and 24 months. Toxicity was graded using CTCAE v5.0. Descriptive statistics were used to summarize patient characteristics and treatment outcomes.
Results: From 2021 to 2024, a total of 20 patients were treated and analyzed. The median age was 72 years (range: 53–91). The majority were men (73.7%) and had right-sided tumors (57.9%). The average tumor size was 32 mm (IQR 22.5–46 mm). The main indication for SBRT was patient unfitness for surgery. The most commonly used treatment scheme was 40 Gy in 5 fractions (65%). LC rates were 100% at 24 months. PFS was 66.7% at 24 months, and OS was 88.9% at 24 months. Grade =3 toxicity was observed in 0% at 6 months and 5.3% at 24 months. One patient developed out-of-field recurrence.
Conclusion: SBRT for renal cancer demonstrated high local control and low toxicity in this academic center, reinforcing its feasibility in middle-income countries. These findings suggest that SBRT could expand access to effective cancer treatment in regions where surgery is not always available. Further studies with longer follow-up and comparative analyses are needed to optimize SBRT implementation in resource-limited settings.